T here is a pressing need to develop novel therapeutic approaches aimed at generating new contractile tissue in patients with myocardial damage. Although there is evidence that, after cardiac injury, a partial attempt at cardiomyocyte regeneration takes place in the damaged areas, 1-3 myocardial repair typically occurs by scarring. A powerful way to boost cardiomyocyte generation in damaged, adult hearts would be to reinitiate or to enhance the developmental program that sustains robust cardiomyocyte proliferation in the embryonic and early neonatal life.
The Notch signaling pathway essentially participates in the process of cardiac development. [4] [5] [6] In particular, we, and others, have shown that, during the last phase of development, Notch activation is essential to sustain proliferation of a pool of still immature cardiomyocytes. [7] [8] [9] [10] At birth, almost half of the proliferating cardiomyocytes in the fetus contain activated Notch1 in their nuclei, and this factor continues to act as a key, positive regulator during the short proliferative window in the early postnatal life. 7 Physiological activation of Notch signaling requires cellcell contact and occurs through binding of one of the 4 Notch receptors (Notch 1-4) to one of their ligands (Delta and Jagged in vertebrates), followed by proteolytic release of the intracellular domain of Notch (Notch-ICD) and its translocation into the nucleus. 11 Once inside the nucleus, the Notch-Many studies have provided evidence that activation of Notch signaling exerts a beneficial effect after heart injury. Transgenic mice overexpressing the Notch1-ICD 15 or its Jagged1 ligand 16 in cardiomyocytes show better response after myocardial damage. Similar findings were also observed when the Notch pathway was activated in the adult mouse myocardium by the hepatocyte growth factor 10 or high mobility group box 1 (HMGBI). 17 Notch1-activated cells were also found enriched in the epicardium in response to myocardial infarction (MI) and aortic banding. 18 Finally, administration of bone morphogenetic protein 10, which is also controlled by Notch, improves cardiac repair after infarction. 19 In the adult zebrafish heart, which is capable of fully regenerating the heart after myocardial damage, 20, 21 the regenerative process is sustained by the reactivation of the Notch pathway in the proliferating cardiomyocytes. 22, 23 In mammals, an attempt at cardiac regeneration also takes place after MI, as indicated by the presence of a small number of proliferating cardiomyocytes in the infarct border zone. 1, 2, 24 This attempt, however, is limited and ineffectual, and healing of the damage by a scarring mechanism prevails.
On the basis of these observations, we wanted to test whether the regenerative capacity of the adult mouse heart might be stimulated by forcing reactivation of the Notch pathway after MI. We took advantage of the possibility to deliver the activated Notch1-ICD or the Jagged1 ligand to the heart using viral vectors based on the adenoassociated virus (AAV), which possess the exquisite capacity to transduce cardiomyocytes at high efficiency and to drive transgene expression in a persistent manner. 25, 26 Here, we show that neonatal cardiomyocytes transduced with the AAV vectors expressing the 2 factors prolong their proliferative potential in culture and that this is paralleled by the preservation of an open chromatin conformation at the Notch1 target genes, characterized by histone 3 lysine 4 trimethylation. Activation of the Notch pathway, however, is largely ineffectual after MI in adult hearts, where the same gene promoters are embedded in a closed chromatin conformation characterized by the presence of permanent, repressive chromatin marks, including histone 3 lysine 27 trimethylation (H3K27me3) and the polycomb group (PcG) complex repressive methylase enhancer of zeste homolog 2 (Ezh2). 27, 28 Furthermore, in adult cardiomyocytes, the DNA sequence of these promoters shows CpG methylation, a mark of irreversible transcriptional repression. 29 We conclude that the induction of adult cardiomyocyte proliferation through Notch pathway stimulation is not a suitable strategy to induce a regenerative response in adult mouse hearts.
Methods
An expanded Methods section is available in the Online Data Supplement.
Animals
Animal care and treatment were according to institutional guidelines and in compliance with national and international laws and policies (European Economic Community Council Directive 86/609, OJL 358, December 12, 1987 ).
Culture of Rat Cardiomyocytes
Culture of ventricular cardiomyocytes from neonatal Wistar rats was performed as previously described. 7 Ventricular cardiomyocytes from adult mice were isolated from Langendorff-perfused hearts of female Wistar rats (2-months old). 30
Chromatin Immunoprecipitation
Chromatin immunoprecipitation was performed as described, 31 with modification detailed in the Methods in the Online Data Supplement. The primers used are listed in Online Table III .
Immunofluorescence and 5-Bromo-2′-Deoxyuridine Detection
Immunofluorescence staining was performed on cultured cardiomyocytes fixed in 4% PFA, as previously described. 7
MI and Echocardiography Analysis
MI was produced in adult female CD1 mice (8-12 weeks old), by permanent left anterior descending coronary artery ligation. AAV transduction was performed with a single injection of recombinant AAV vectors, at a dose of 1×10 11 viral genomes per animal, into the myocardium bordering the infarct zone. Evaluation of cardiac function was achieved using a Visual Sonics Vevo 770 Ultrasound (Visual Sonics) equipped with a 30-MHz linear array transducer.
AAV Vector Production and Transduction
The AAV vectors used in this study were generated by the AAV Vector Unit at International Centre for Genetic Engineering and Biotechnology Trieste (http://www.icgeb.org/avu-core-facility.html) according to established procedures, as detailed in the Methods in the Online Data Supplement. All vectors are based on the AAV2 genome, and the transgenes are driven by the cytomegalovirus immediate early promoter.
Neonatal cardiomyocytes were transduced contextually to plating with at multiplicity of infection=1×10 4 vg per cell. Adult cardiomyocytes were transduced the day after plating at multiplicity of infec-tion=1×10 4 vg per cell. To evaluate AAV persistence and expression in vivo, animals were injected intraperitoneally with AAVs (2.25×10 10 vg/g body weight). Heart samples were collected at 7, 14, 30, and 60 days after injection.
Bisulfite Sequencing
Genomic DNA (1 µg) extracted from cardiomyocytes in culture was treated for DNA conversion with sodium bisulfite using EpiTect Bisulfite Kit (Qiagen) according to manufacturer's instruction. Promoter sequences were analyzed with using Methyl Primer Express Software v1.0 (Applied Biosystems) to predict CpG islands. Primer sequences were designed using the same software and are listed in Online Table IV . Amplified fragments were separated on 2% agarose gel, visualized with ethidium bromide staining, and then purified from gel using Wizard SV Gel and Polymerase Chain Reaction Clean-up system kit (Promega). The purified DNA was cloned into TOPO T/A cloning kit (Invitrogen). Eight randomly picked clones were sequenced and analyzed using BiQ analyzer. 32 
Nonstandard Abbreviations and Acronyms

AAV adenoassociated virus
AzaC
5-Aza-2´-deoxycytidine
BrdU 
5-bromo-2′-deoxyuridine
Statistical Analysis
All data are presented as mean±SEM. Statistical analysis was performed using Prism Software (GraphPad), using 1-way ANOVA followed by Bonferroni post hoc test for the comparison of ≥3 groups.
Results
Decrease of Cardiomyocyte Proliferation After Birth Coincides With Markedly Reduced Notch Signaling
The extent of neonatal rat cardiomyocytes proliferation, as measured by 5-bromo-2′-deoxyuridine (BrdU) incorporation, progressively declined after birth, as shown in Figure 1A by comparing cardiomyocytes at day 3 versus day 7 after isolation (P<0.01), consistent with previous results. 7 Virtually no BrdU incorporation was detectable in cardiomyocytes from adult (2-months old) rats. In the same samples, the levels of the Notch1 mRNA were markedly decreased at day 7 when compared with that at day-3 cardiomyocytes, reaching levels similar to those found in adult cells (P<0.01). The mRNA levels for the Notch1 target genes Hes1, Hey1, Hey2, 5 and the proliferation-associated gene Cyclin D1 8 showed a parallel decline for both day 7 and adult cardiomyocytes when compared with day-3 cells ( Figure 1B ).
Loss of Cardiomyocyte Proliferation Parallels the Establishment of Repressive Chromatin at Notch-Responsive Genes
To understand the molecular correlates accompanying the loss of Notch signaling, we analyzed chromatin at the promoters of the Notch-responsive genes Hes1, Hey1, Hey2, Notch1, and Cyclin D1 in day-3 (proliferating), day-7 (quiescent), and adult cardiomyocytes; the GAPDH promoter served as a control. For each of these genes, sets of primers were designed and validated, mapping in correspondence of the gene transcription start sites (TSSs; Figure 1C ). Chromatin immunoprecipitation experiments were performed by immunoprecipitating chromatin using antibodies against 2 marks correlating with active chromatin (acetylated and lysine 4-trimethylated histone 3, H3panAc, and histone 3 lysine 4 trimethylation, respectively) and 2 marks of transcriptionally repressed chromatin. The last 2 modifications were related to transcriptional suppression by the PcG complex of proteins and included H3K27me3 and the presence of the Ezh2 methylase enzyme itself. When cells actively proliferated (day 3), the Notchresponsive gene promoters were marked by the active chromatin marks H3panAc and histone 3 lysine 4 trimethylation. On neonatal day 7 and adult cardiomyocytes, no changes were detected at the GAPDH promoter ( Figure 1D ). On the contrary, on day-7 and in adult cardiomyocytes, the Notch target gene promoters were marked by the repressive H3K27me3 modification and were occupied by Ezh2 ( Figure 1E ).
Increased Ezh2 occupancy at the Notch-responsive promoters was unrelated to changes in Ezh2 expression levels (Online Figure IA) .
We conclude that a shift from active to repressive chromatin occurs at the Notch-related promoters concomitant with the cells exiting the proliferative phase.
Activation of the Notch Pathway by AAV-Mediated Gene Transfer Promotes Neonatal Rat Cardiomyocyte Proliferation
Given the correlation between Notch1 levels and the extent of cardiomyocyte proliferation, and considering the established role of Notch1 in driving proliferation of these cells during the last phase of cardiac development, [7] [8] [9] we wondered whether the forced activation of the Notch pathway might extend the proliferative window of neonatal cardiomyocytes. We took advantage of the properties of AAV serotype 6 (AAV6) vectors to transduce these cells at high efficiency 26 (Online Figure IIA and IIB). We obtained 2 AAV6 vectors, one coding for the constitutively active N1ICD (AAV6-N1ICD) and the other for the soluble form of the ligand Jagged1 (AAV6-sJ1). The latter is secreted by the transduced cells and activates Notch signaling in a contact-independent manner, therefore, acting as a soluble cytokine 7, 33 ; Figure 2A . Neonatal rat cardiomyocytes were transduced after isolation at birth (multiplicity of infection=1×10 4 vg per cell) with either of the 2 vectors; in both cases, transgene expression was sustained at both days 3 and 7 ( Figure 2B ). Exogenously introduced N1ICD interacted with cellular RBP-Jk protein (Online Figure III) .
Transduction markedly increased the number of proliferating cardiomyocytes, as evaluated by pulsing the cardiomyocyte cultures with BrdU for 24 hours before assessing the number of BrdU-positive nuclei by immunofluorescence ( Figure 2C In the case of AAV6-N1ICDtransduced cardiomyocytes, the fraction of α-actinin+, BrdU+ cells was 14.5% at day 3 and 18.7% at day 7, to be compared with 9.4% and 4.1% in cells transduced with a control AAV6 vector (P<0.05 and P<0.01, respectively). Instead, proliferation did not increase at day 3 in the cultures transduced with AAV6-sJ1; however, it was remarkably higher than control at day 7 (15.7% proliferating cells; P<0.01; Figure 2D ). These different kinetics most likely reflect the requirement of sJ1 to accumulate in the extracellular environment in order for the soluble ligand to cluster and activate the Notch pathway. [33] [34] [35] [36] Activity of AAV6-sJ1, but not that of AAV6-N1ICD, was dependent on endogenous Notch1 receptor because it was inhibited by DAPT (N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester) treatment (Online Figure V) .
In the same transduced cultures, we also assessed the levels of the mRNAs for the endogenous Notch1 gene and its targets. These were found to parallel the extent of cardiomyocyte proliferation, reaching statistical significance for N1ICD already at day 3 for some targets, and for all targets and both vectors at day 7 ( Figure 2E ). Activation of the Notch pathway by AAV6-N1ICD at days 3 and 7 and AAV6-sJ1 at day 7 also resulted in the increase of endogenous Notch1 expression, consistent with the existence of a positive feedback loop. 14, 15 We further analyzed whether the chromatin environment at the Notch-responsive promoters was influenced by constitutive Notch signaling stimulation. Chromatin immunoprecipitation experiments were performed on neonatal rat cardiomyocytes infected at the day of isolation with either AAV6-N1ICD or AAV6-sJ1. Cells were kept in culture for 3 or 7 days, to evaluate the chromatin profile in the same settings in which gene expression and proliferation levels were previously analyzed. In cells transduced with AAV6-N1ICD, day-7 chromatin was significantly more acetylated than in control-treated cardiomyocytes at the analyzed Notch1 responsive genes ( Figure 3A) . Instead, the amount of chromatin immunoprecipitated with the anti-H3K27me3 and the anti-Ezh2 antibodies increased in control conditions at day 7, whereas it remained stable in the cells transduced with AAV6-N1ICD ( Figure 3B and 3C respectively). A similar pattern was also observed in cells transduced with the AAV6-sJ1 vector. The levels of Ezh2 were unchanged in cells transduced with the vectors (Online Figure IB) .
To confirm the role of PcG-induced chromatin modification in Notch pathway silencing further, we treated cardiomyocytes with the Ezh2 inhibitor N- 37 These experiments were performed in 5 conditions (Figure 4Aa-e ). The drug had no significant effect on (H3K27me3; B) , and enhancer of zeste homolog 2 (Ezh2; C). Shown are the mean±SEM of ≥3 independent experiments. The lines joining day-3 and day-7 samples are meant to show a trend, not necessarily assuming that the increase in the histone marks was linear. September 12, 2014 cardiomyocyte proliferation, as assessed by BrdU incorporation, at day 3, when spontaneous proliferation still occurs (a versus b). However, when proliferation was analyzed at day 7, after the drug was administered from day 5, proliferation was induced at a level comparable with that of AAV6-N1ICD (c versus d; 5.2% versus 16.3%; P<0.01). Even more important, when GSK126 treatment had started at day 3, Notch pathway activation through N1ICD was able to increase the extent of proliferation further (e; 22.2% BrdU+-cardiomyocytes; P<0.05% compared with untreated). Efficiency of GSK126 treatment in inhibiting Ezh2 was confirmed by analyzing the levels of H3K27me3 ( Figure 4B and 4C) . These experiments show that Ezh2 inhibition and Notch signaling have a synergistic effect in promoting cardiomyocyte proliferation.
Collectively, these results indicate that stimulation of the Notch pathway by gene transfer can significantly expand the proliferative capacity of neonatal cardiomyocytes, maintaining an open chromatin conformation at the Notch-responsive genes and thus sustaining high levels of transcription.
AAV-Mediated Notch Pathway Activation Is Ineffective After MI in Adult Mice
Next, we wanted to assess whether the vectors expressing activated Notch1 and Jagged1 might also improve the outcome of MI by promoting tissue regeneration in vivo. After permanent ligation of the left anterior descending coronary artery in adult CD1 mice, AAV serotype 9 vectors encoding N1ICD or sJ1 were injected in the peri-infarct zone along with an AAV9 vector containing an empty multiple cloning site as a control (n=12 per group). AAV9 gene delivery in vivo was effective, as concluded by quantitative polymerase chain reaction analysis for vector DNA at days 7, 14, 30, and 60 after transduction (n=3 per group per time; Figure 5A ) and in agreement with published observations. 38 In particular, the number of vector genomes in the heart was the highest at 7 days after transduction, decreased at day 14 and remained stable afterward, consistent with our previous results. 26, 30 Transgene expression paralleled the levels of transduction and remained relatively high for the whole duration of the experiment ( Figure 5B and 5C for mRNA and protein levels, respectively). Assessment of cardiac function was monitored by echocardiography ≤2 months after MI and AAV9 vector delivery. Contrary to our expectations, mice transduced with either vector displayed no significantly better cardiac performance than those injected with the control AAV9 vector. Figure 5D to 5H reports left ventricular (LV) ejection fraction ( Figure 5D ), LV fractional shortening ( Figure 5E ), LV anterior wall thickening ( Figure 5F ), LV systolic ( Figure 5G ), and LV diastolic ( Figure 5H ) anterior wall thickness (LV anterior wall thickening-systolic and LV anterior wall thickening-diastolic) for the 3 groups of animals, at days 7, 14, 30, and 60 after MI (P=ns at all time points for either group versus control). The absence of a significant regenerative response in the injected animals was confirmed by the lack of scar size reduction at anatomic and histological examination (representative Masson trichrome staining and quantification of the infarct size are provided in Figure 5I and 5J, respectively).
Forced Activation of the Notch Pathway Does Not Induce Adult Cardiomyocyte Proliferation
To understand the cause underlying the lack of Notch1 effect after MI in vivo, we tested the effect of Notch1 activation in adult rat cardiomyocytes. Similar to neonatal cells, adult cardiomyocytes were also effectively transduced by AAV serotype 6 (>40% of transduced cardiomyocytes in either serum-free conditions or the presence of 5% fetal bovine serum, which is required for adult cardiomyocyte proliferation 30 We evaluated the effect of AAV6-N1ICD and AAV6-sJ1 on the proliferation of these cells, and compared these results with those obtained after transduction with 2 other AAV6 vectors, containing the precursor genes for miR-199a and miR-590, 2 of the miRNAs that we recently showed to activate neonatal and adult cardiomyocyte proliferation, both in vitro and in vivo. 30 At day 9 after transduction, no significant proliferation (as evaluated by BrdU incorporation) was observed in the cardiomyocytes transduced with AAV6-N1ICD or AAV6-sJ1, whereas 5.7% and 16.2% of BrdU-positive cells were found in the cultures transduced with AAV6-mir199a or AAV6-mir590, respectively (representative images and quantification are shown in Figure 6A and 6B, respectively). Absence of proliferation in the cardiomyocytes transduced with either of the 2 Notch pathway vectors was also confirmed by the lack of positivity to the Ki-67 and phospho-histone H3 proliferation markers (not shown).
These results clearly indicate that forcing activation of the Notch1 pathway by AAV-mediated gene transfer is ineffective in driving proliferation of adult cardiomyocytes, in contrast to the effect of other treatments, such as the investigated miRNAs. We also noticed that the levels of Notch1 itself and of its target genes Hes1, Hey1, Hey2, and Cyclin D1 did not significantly increase in the cells treated with AAV6-mir199a or AAV6-mir590, indicating that the molecular route through which these miRNAs function does not involve reactivation of the Notch pathway ( Figure 6C ).
Notch Target Genes Are Modified by CpG Methylation in Adult Cardiomyocytes
We wanted to understand the molecular reason why gene transfer did not reactivate Notch signaling in adult cardiomyocytes. Because promoter methylation is commonly associated with permanent and irreversible transcriptional repression, we analyzed the DNA methylation status of Notch1 and its target genes Hes1, Hey1, Hey2, and Cyclin D1. In particular, we identified the CpG-rich areas in the genomic regions in correspondence of the gene TSSs. Then, by bisulfite sequencing, 39 we compared the levels of methylation at 2 selected segments inside these areas, one upstream and another downstream the TSS, in day-3 and day-7 neonatal and in adult cardiomyocytes.
At day 3, the extent of DNA methylation at the Notch1 gene was relatively low (2.5% of the CpG dinucleotides analyzed upstream the TSS and 1.8% downstream the TSS). These levels markedly increased in day-7 cells (20.0% and 4.9%, respectively) and in adult cardiomyocytes (36.2% and 12.9%, respectively; P<0.01 for both primer sets, adult versus day 3; Figure 7A ). Analogous results were obtained by analyzing the Hes1 gene. At day 3, 2.7% of the CpGs in the analyzed regions upstream the TSS scored positive for methylation and 2.3% in the region downstream the TSS. These levels rose to 4.2% and 8.6% at day 7 and to 15.3% and 22.7%, respectively, in adult cardiomyocytes (P<0.01 for both primer sets, adult versus day-3 cells; Figure 7B ). Analogous results were obtained for Hey1 and Hey2, even if less pronounced, overall showing increased methylation in day-7 and adult cardiomyocytes compared with day-3 cells ( Figure 7C and 7D, respectively). Of potential interest, the Cyclin D1 promoter, however, showed a different pattern, with scattered methylation also occurring in day-3 samples in the more upstream GC-rich region (2.5 kb upstream the TSS), not correlated with transcriptional silencing, whereas the CpG island close to the TSS (explored by primer set D) remained unmethylated ( Figure 7E ). This result is in keeping with the requirement for Cyclin D1 re-expression when proliferation of adult cardiomyocytes is triggered by other stimuli, including miRNAs. 30 Analysis of the TSS regions of GAPDH, a housekeeping gene, and glial fibrillary acidic protein, a glial gene silenced in cardiomyocytes, served as negative and positive controls for methylation, respectively ( Figure 7F and 7G, respectively).
To confirm that DNA methylation at the Notch target gene promoters effectively represses transcription, we generated plasmid constructs in which the Notch1, Hes1, Hey1, and Hey2 gene promoters were cloned upstream of the luciferase reporter gene and submitted these constructs to in vitro methylation using the SssI CpG methyltransferase and the methyl donor S-adenosyl-methionine, followed by transfection of neonatal rat cardiomyocytes. We found that in vitro methylation markedly blunted luciferase activity at both days 3 and 7 (Online Figure VIA and VIB, respectively). Efficiency of methylation was assessed by comparing DNA sensitivity with that of the MspI/HpaII restriction enzyme isoschizomers (Online Figure VIC) ; samples incubated without S-adenosyl-methionine served as a control.
Consistent with the repressive role of Notch gene promoter methylation, treatment with 5-Aza-2′deoxycytidine (AzaC), a nucleotide analog that prevents DNA methylation, significantly increased neonatal cardiomyocytes proliferation (4.2% Brdu+ cardiomyocytes versus 15.0% when AzaC was administered between days 1 and 3, and proliferation was analyzed at day 7; P<0.01; Figure 8A ). The drug markedly synergized with AAV6-N1ICD when this was administered immediately after cell plating (25.9%; P<0.01 versus AzaC alone). Most relevant, the drug was able to rescue the relatively poorer efficacy of AAV6-N1ICD when this was administered at day 4 (26.2% versus 10.9%; BrdU+ cardiomyocytes with or without AzaC). This result is consistent with the conclusion that impeding the establishment of methylation favors the effect of N1ICD. The effectiveness of AzaC in preventing methylation was verified at the Notch1, Hes1 promoters, and glial fibrillary acidic protein promoters by bisulfite sequencing (comparative results in Figure 8B and sequencing data in Online Figure VII) .
These results indicate that terminal differentiation of cardiomyocytes correlates with progressive DNA methylation of the Notch1 target genes and provide a molecular explanation for the inefficacy of the treatments aimed at reactivating expression of these genes by gene transfer.
Discussion
Our work shows that, during the early postnatal life, the Notch pathway sustains active cardiomyocyte proliferation and that cardiomyocyte withdrawal from the cell cycle coincides with epigenetic suppression at the Notch target genes. By analyzing the promoter proximal chromatin of the Hes1, Hey1, Hey2, Cyclin D1, and Notch1 gene itself, we observed that, in cardiomyocytes analyzed immediately after birth, when a significant proportion of cells still proliferate, these regions were organized in an open chromatin status. This was characterized by pan acetylation of histone H3 and trimethylation of H3K4, 2 broad marks of transcriptionally competent chromatin. 40, 41 In contrast, 1 week after birth and in the adult life, the same regions were modified by the H3K27me3 mark, which is associated with chromatin condensation and gene silencing. 28, 42 This mark is typically deposited by the PcG PRC2 complex, which includes the Ezh2 methyltransferase, the only enzyme capable to induce bi-and trimethylation to H3K27 in mammalian cells. 27, 43, 44 Accordingly, we found that this enzyme was present at these silenced promoter regions in neonatal day-7 and in adult cardiomyocytes.
Suppression of the Notch pathway by chromatin modification at the Notch target promoters also occurs in other developmental conditions. In Drosophila, the PcG PRC1 binds to multiple components in the Notch signaling pathway to control proliferation. 45 In the dystrophic skeletal muscle, tumor necrosis factor-α suppresses Notch1 by promoting recruitment of Ezh2 to the Notch-responsive promoters. 46 Also in the developing myocardium, endothelial deletion of Jarid2, a member of the Jumonji family of proteins that is not active as a demethylase but associates with the PcG complex to modulate its function, 47, 48 derepresses endocardial Notch1 expression. 49 In addition, deletion of Ezh2 in cardiac progenitors is known to cause postnatal myocardial pathology. 50 In neonatal cardiomyocytes, chromatin-mediated suppression of the Notch target genes was effectively counteracted by the forced activation of the Notch pathway on AAV-mediated gene transfer. Transduction correlated with persistence of active chromatin marks at the investigated Notch promoters and higher levels of transcription of the corresponding genes, with the ultimate result of driving proliferation of the transduced cells. Of interest, a proliferative response was observed by both the constitutively active N1ICD and the soluble form of its ligand Jagged1. The target cell population of the 2 factors is conceptually different: although N1ICD transduction forces Notch pathway activation by directly acting on the target genes in the nucleus, the soluble form of the ligand requires the cognate receptor to be expressed on the cell surface. Therefore, the timing and strength of the response were different: although N1ICD was able to increase cardiomyocyte proliferation immediately, such proliferative response was only detectable after 1 week in the Jagged1-transduced cells. This delayed response also accounts for the need of soluble Jagged1 to reach a minimum concentration in the extracellular environment to activate downstream signaling. 51 The inefficacy of Notch pathway reactivation by gene transfer to drive adult cardiomyocyte proliferation ex vivo and cardiac regeneration after MI does not seem to be the consequence of an intrinsic incapacity of adult cardiomyocytes to proliferate. Other stimuli, including periostin, 52 neuregulin, 53 FGF1 together with a p38 inhibitor, 54 have all been shown capable to stimulate cardiomyocyte DNA synthesis, karyokinesis, and cytokinesis. In particular, we have recently described a series of microRNAs that induce re-entry of adult cardiomyocytes into the cell cycle and promote cardiac regeneration after MI. 30 Of interest, cell cycle reactivation by 2 of these mi-croRNAs (miR-590 and miR-199a) does not seem to correlate with the reactivation of the Notch pathway, as concluded by the lack of transcriptional activation of the Notch target genes. Taking the lack of effect of Notch transduction and the lack of Notch gene activation after miRNA treatment together, it can be concluded that the induction of adult cardiomyocyte proliferation can no longer be sustained by the Notch pathway because it is in neonatal cells.
Why is N1CD ineffective in adult cardiomyocytes? This can be correlated to the high level of CpG DNA methylation observed in adult cardiomyocytes at the Notch1 and Hes1 gene promoter proximal regions. Indeed, DNA methylation is a well-established modification that correlates with the permanent suppression of gene expression. 55 A context-dependent crosstalk between PcG and DNA methylation has already been demonstrated in different systems, 56, 57 with the PcG protein Ezh2 directly controlling DNA methylation. 58 These include the Notch promoter in skeletal muscle satellite 46 and B acute leukemia cells. 59 The lack of a regenerative effect of AAV9-mediated Notch1 and soluble Jagged1 gene transfer in vivo does not necessarily contrast with previous reports that have shown a beneficial effect of the genetic reactivation of the Notch pathway in transgenic animals. In this respect, it should be considered that AAV vectors are outstanding tools for gene transfer into postmitotic cells and that their efficiency, in the heart, increases with terminal cardiomyocyte differentiation. 26 Thus, although our experiments rule out a direct effect of Notch pathway reactivation in driving adult cardiomyocyte proliferation in vitro and in vivo, they still remain compatible with the possibility that Notch signaling in adults hearts might exert beneficial effects in other cell types, such as in epicardial cells, 18 mesenchymal stromal cells, 16 bonemarrow-derived cells, 60 or cardiomyocyte precursors derived from cardiac stem cells. 9, 17 Reactivation of Notch1 expression after MI in α-myosin heavy chain-mER-Cre-mER transgenic mice showed a positive effect, which was mainly attributed to the preservation of cardiomyocyte viability and the stimulation of angiogenesis, with no evidence of a major regenerative effect. 15 A possible beneficial effect of Notch pathway stimulation in cardiac cells other than cardiomyocytes can also be inferred from our study, where soluble Jagged1 transduction produced a marginal improvement in cardiac function, albeit not statistically significant in the groups of animals analyzed, which can be attributed to a paracrine effect.
In conclusion, contrary to other conditions, such as brain ischemia 61 and skeletal muscle injury, 62 where reactivation of Notch signaling promotes tissue repair, attempts at inducing cardiac regeneration after MI by reactivation of the Notch pathway in cardiomyocytes by gene transfer are ineffective. This observation contrasts with the assumption that tissue regeneration in adult organisms has to recapitulate the events occurring during development. A parallel situation also exists for other organs. For instance, the satellite cell transcription factor Pax7 is required for skeletal muscle regeneration in neonatal mice but is dispensable for regeneration during juvenile and adult stages. 63 In both cardiac and skeletal muscle, therefore, it seems that a distinction exists between the molecular mechanisms driving development and those responsible for further maintenance, expansion, and repair of the differentiated tissues. How to exploit these adult mechanisms for therapeutic purposes continues to remain a highly sought after target for future investigation.
